Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means patients lived longer without their cancer growing or spreading, compared with ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the steepest drop observed during 2021–2023. Transition from cytotoxic ...

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Please provide your email address to receive an email when new articles are posted on . A single infusion of cilta-cel induced minimal residual disease negativity in all 20 treated patients. MRD ...

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD. “We are living in a really ...

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD. Bispecific ...

Twenty patients with high-risk smoldering multiple myeloma (SMM) remained negative for minimal residual disease (MRD) for more than 15 months after a single infusion of the CAR-T cell therapy ...